AIFORIANasdaq HelsinkiHealth Information ServicesIFRS · EUR

Aiforia Technologies Oyj

Aiforia is a Finnish company specializing in developing AI-powered image analysis software for medical research and diagnostics. The company aims to enhance healthcare outcomes by enabling precise diagnoses and personalized patient care. Aiforia's solutions cater to the growing demand for digital pathology, driven by an aging population and the increasing prevalence of diseases like cancer. The company's offerings streamline medical image analysis across various fields, including oncology and neuroscience, through its deep-learning software solutions and expert services.

Revenue3.5m EUR
+23.9 %y/y
Operating profit (EBIT)-11.2m EUR
+8.3 %y/y
EBIT margin-316.4%
+111.2 ppy/y
Net income-12.7m EUR
−6.0 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-15-10-505m EUR2021: 0.97 m EUR2021: EBIT -4.7 m EUR20212022: 1.9 m EUR2022: EBIT -10 m EUR20222023: 2.4 m EUR2023: EBIT -13 m EUR20232024: 2.9 m EUR2024: EBIT -12 m EUR20242025: 3.5 m EUR2025: EBIT -11 m EUR20253.5-11
RevenueOperating profit (EBIT)

Business

Share of revenue
AI Image Analysis Software40 %

AI-powered software for medical research and diagnostics.

SaaS Solutions30 %

Subscription-based software for pathology diagnostics.

Custom Expert Services15 %

Tailored services for researchers and pathologists.

Clinical Solutions15 %

AI solutions to enhance hospital efficiency and diagnostics.

Customers

Aiforia's customer base includes researchers, pathologists, and hospitals seeking to enhance diagnostic accuracy and efficiency. The company's AI solutions are particularly appealing to medical professionals involved in oncology and neuroscience, where precise image analysis is critical. Hospitals and laboratories undergoing digital transformation are key customers, leveraging Aiforia's tools to improve workflow and patient outcomes. The company's platform also attracts researchers developing new biomarkers and drugs, providing them with advanced AI models to accelerate their work.

Researchers

Use AI for advanced medical studies and biomarker discovery.

Pathologists

Seek efficient diagnostic tools to streamline workflows.

Hospitals

Aim to improve diagnostic accuracy and patient outcomes.

Laboratories

Undergoing digital transformation with AI solutions.

Strategy

Aiforia's strategic priorities focus on expanding its product offerings and achieving profitability by 2027. The company aims to cover 80% of pathologists' diagnostic workflows with its solutions and reach over €100 million in revenue. Aiforia is also focused on forming strategic partnerships and increasing its presence in key markets. By leveraging its AI technology, the company seeks to enhance its competitive position and drive growth in the digital pathology sector.

Expand product offeringsMedium term

To cover 80% of diagnostic workflows

Achieve profitabilityLong term

To ensure sustainable growth

Increase revenueMedium term

To reach over €100 million

Geography

Aiforia is headquartered in Finland and has a significant presence in the United States, where a large portion of its revenue is generated. The company has also expanded its operations in Europe, establishing a subsidiary in France to strengthen its local presence. Aiforia's geographic focus includes key markets in North America and Europe, where the demand for digital pathology solutions is growing. This international presence helps Aiforia mitigate currency risks and leverage regional market opportunities.

Risks

Aiforia faces several risks, including financial instability due to its current unprofitable status and reliance on external funding. Currency fluctuations, particularly with the US dollar, pose a risk given the company's significant revenue from the US market. Additionally, the success of Aiforia's product development and the retention of key personnel are critical to its future prospects. The company is also exposed to regulatory risks, especially in the evolving landscape of medical device regulations.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Financial instability1Product development success2Currency fluctuations3Regulatory changes4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Financial instabilityImpact: CriticalLikelihood: High

    Current unprofitable status and funding reliance

  2. Product development successImpact: HighLikelihood: Medium

    Critical for future growth

  3. Currency fluctuationsImpact: HighLikelihood: Low

    Significant revenue from US market

  4. Regulatory changesImpact: MediumLikelihood: Medium

    Evolving medical device regulations

Accounting

Judgemental items
Revenue recognition timing

Affects reported revenue in SaaS model

Impact: high

Capitalization of development costs

Impacts balance sheet and future expenses

Impact: medium

Currency fluctuations

Affects international financial results

Impact: medium

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026

Aiforia Technologies Oyj (AIFORIA) Revenue, Earnings & Financials 2025 – Clarifo